| 616.63 6.74 (1.11%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 750.6 |
1-year : | 876.71 |
| Resists | First : | 642.64 |
Second : | 750.6 |
| Pivot price | 612.54  |
|||
| Supports | First : | 602.47 |
Second : | 577.64 |
| MAs | MA(5) : | 612.26 |
MA(20) : | 614.36 |
| MA(100) : | 557.57 |
MA(250) : | 535.88 |
|
| MACD | MACD : | 2.8 |
Signal : | 3.5 |
| %K %D | K(14,3) : | 50.9 |
D(3) : | 47.6 |
| RSI | RSI(14): 53.8 |
|||
| 52-week | High : | 677.9 | Low : | 373 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MEDP ] has closed below upper band by 38.2%. Bollinger Bands are 46% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 631.34 - 634.33 | 634.33 - 637.14 |
| Low: | 598.19 - 601.59 | 601.59 - 604.79 |
| Close: | 611.06 - 616.39 | 616.39 - 621.4 |
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Wed, 14 Oct 2026
Medpace Holdings, Inc. (MEDP) Stock Forecasts - Yahoo Finance
Wed, 14 Oct 2026
At $166.73 a share, Medpace (MEDP) EVP Susan E. Burwig exercised options for 3,000 shares. - Stock Titan
Wed, 14 Oct 2026
Medpace Holdings: Strong Bookings, But Pass-Through Flatters Growth And The Valuation Leaves Little Room - Seeking Alpha
Tue, 13 Oct 2026
Medpace: Strong Execution Faces A High-Growth Bar (NASDAQ:MEDP) - Seeking Alpha
Tue, 13 Oct 2026
Medpace: A Shorter, Cleaner Backlog Is Being Mistaken For A Smaller One (NASDAQ:MEDP) - Seeking Alpha
Tue, 13 Oct 2026
Form 4 Medpace Holdings Inc: Brian T. Carley (Director) For: 30 September - Investing.com Nigeria
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 28 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 18.7 (%) |
| Held by Institutions | 91.3 (%) |
| Shares Short | 1,600 (K) |
| Shares Short P.Month | 1,670 (K) |
| EPS | 17.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 15.55 |
| Profit Margin | 17.6 % |
| Operating Margin | 20.7 % |
| Return on Assets (ttm) | 20.1 % |
| Return on Equity (ttm) | 162.1 % |
| Qtrly Rev. Growth | 17.2 % |
| Gross Profit (p.s.) | 72.01 |
| Sales Per Share | 99.6 |
| EBITDA (p.s.) | 21.89 |
| Qtrly Earnings Growth | 37 % |
| Operating Cash Flow | 753 (M) |
| Levered Free Cash Flow | 510 (M) |
| PE Ratio | 36.2 |
| PEG Ratio | 2.8 |
| Price to Book value | 39.65 |
| Price to Sales | 6.19 |
| Price to Cash Flow | 22.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|